Outcomes in Patients with Hematological Malignancies Receiving Anti-CD20 Therapy in the Setting of COVID-19 Infection

Objective: The global COVID-19 pandemic has posed a major challenge for patients with hematological malignancies undergoing treatment. For patients with acute leukemia and aggressive lymphomas, delaying curative chemotherapy treatments has historically been associated with adverse outcomes. In the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Carlos A, Chitty, David, Chi, Jeffrey, Saif, Wasif, Goldberg, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
902.Health Services Research-Malignant Conditions (Lymphoid Disease)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330338/
http://dx.doi.org/10.1182/blood-2020-143124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330338/
http://dx.doi.org/10.1182/blood-2020-143124

Ejemplares similares